Acme United Corp (ACU) News & EventsACUNews & EventsAcme United Corp

Acme United Reports Q1 Revenue of $52.3M

Reports Q1 revenue $52.3M vs. $46.0M last year. CEO Walter Johnsen said, "While we experienced higher costs of sales and operating expenses in Q1, the impact was magnified due to the seasonality of our business, which traditionally has lower sales in Q1. We are actively working to improve profitability...My Medic, which has annual sales of $19M, offers many compelling growth and cost saving opportunities. We are expanding My Medic's retail distribution while also leveraging Acme United's strong purchasing network to reduce costs, cutting overhead, and consolidating functions. Importantly, the expenses incurred for the enhanced quality assurance protocols at the Med-Nap facility were one-time, non-recurring expenses...To date, we have added approximately $10M of incremental orders for delivery in the second and third quarters and are carefully evaluating additional purchases. Acme United has extensive experience with supply chain challenges, and I am confident that our team will address them successfully. I also believe the investments we have been making in expanding Acme United's business lines, technology, and capacity will continue to strengthen our company."

Acme United Acquires My Medic Assets for $18.7 Million

Acme United has acquired the assets of SLED Distribution, doing business as My Medic, a supplier of tactical, trauma and emergency response products, primarily in the direct-to-consumer channel. My Medic had revenues in 2025 of approximately $19M. Established in 2014, the company is located in North Salt Lake, Utah and employs 40 people. The purchase price of the acquisition was $18.7M. At closing, the company paid $14.6 million to My Medic. The $4.1M balance of the purchase price is subject to holdbacks as follows: (a) $1,000,000, the payment of which is contingent upon certain revenue milestones during the twelve months ended December 31, 2027; and (b) $3.1M, which is subject to a holdback as a non-exclusive source of recovery primarily to satisfy indemnification claims under the Asset Purchase Agreement.

Acumen Pharmaceuticals Enhances Antibody Delivery for Alzheimer's at CTAD 2025

Acumen Pharmaceuticals announced new research at the 18th Annual Clinical Trials on Alzheimer's Disease, CTAD, conference, taking place December 1-4, 2025, in San Diego and online. Results from a collaborative study with JCR Pharmaceuticals demonstrated improved delivery of AbetaO-targeting monoclonal antibodies to the central nervous system, including sabirnetug, ACU193, through the blood-brain barrier using the transferrin receptor pathway, which is being developed to potentially increase and broaden brain distribution and maximize the efficacy-to-safety ratio. Building on these results, Acumen and JCR Pharmaceuticals are now developing TfR-targeting antibodies for clinical testing. Additionally, results on clinical trial recruitment from the Phase 2 ALTITUDE-AD clinical trial showed that site databases and physician referrals were the most reliable recruitment methods overall.